Serum hepatitis B virus surface antigen (HBsAg) levels have been suggested to predict interferon response in chronic hepatitis B. A few data are available on the role of HBsAg measurement in nucleos(t)ide analogues (NA) treatment. We retrospectively investigated the relation between HBsAg changes and main treatment outcomes during long-term lamivudine treatment in hepatitis e antigen (HBeAg)-negative chronic hepatitis B. A total of 42 HBeAg-negative patients were consecutively enrolled in an open-label study on long-term lamivudine monotherapy (150 mg/die). Serum HBsAg levels were quantified every 6 months by Architect assay (Abbott Diagnostics). HBV-DNA was quantified quarterly by real-time PCR (Roche Diagnostics). The median duration of lamivudine treatment was 66 months (20-153). One patient (2%) was a primary nonresponder, 35 (83%) developed virological breakthrough (VB) and the remaining six patients (14%) were classified as long-term on-treatment responders. During treatment, HBsAg levels decreased only in long-term on-treatment responders, while no changes were observed in resistant patients. Failure to achieve a decrease of 0.7 log(10) IU/mL in serum HBsAg at month six of lamivudine had a positive predictive value of developing VB of 90% and a negative predictive value of 100%. These high predictive values were also maintained in the subgroup of patients negative for HBV-DNA at month six. The results of this study with a small sample size suggest a role of on-treatment HBsAg quantification in the management of lamivudine-treated patients. If validated prospectively in a larger patient cohort, HBsAg measurements would be a useful adjunct to optimize antiviral therapy.

Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients / Gramenzi, Annagiulia; Loggi, Elisabetta; Micco, Lorenzo; Cursaro, C; Fiorino, S; Galli, S; Gitto, Stefano; Galli, C; Furlini, G; Bernardi, Mauro; Andreone, Pietro. - In: JOURNAL OF VIRAL HEPATITIS. - ISSN 1352-0504. - 18:10(2011), pp. e468-e474. [10.1111/j.1365-2893.2011.01473.x]

Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients

BERNARDI, MAURO;ANDREONE, PIETRO
2011

Abstract

Serum hepatitis B virus surface antigen (HBsAg) levels have been suggested to predict interferon response in chronic hepatitis B. A few data are available on the role of HBsAg measurement in nucleos(t)ide analogues (NA) treatment. We retrospectively investigated the relation between HBsAg changes and main treatment outcomes during long-term lamivudine treatment in hepatitis e antigen (HBeAg)-negative chronic hepatitis B. A total of 42 HBeAg-negative patients were consecutively enrolled in an open-label study on long-term lamivudine monotherapy (150 mg/die). Serum HBsAg levels were quantified every 6 months by Architect assay (Abbott Diagnostics). HBV-DNA was quantified quarterly by real-time PCR (Roche Diagnostics). The median duration of lamivudine treatment was 66 months (20-153). One patient (2%) was a primary nonresponder, 35 (83%) developed virological breakthrough (VB) and the remaining six patients (14%) were classified as long-term on-treatment responders. During treatment, HBsAg levels decreased only in long-term on-treatment responders, while no changes were observed in resistant patients. Failure to achieve a decrease of 0.7 log(10) IU/mL in serum HBsAg at month six of lamivudine had a positive predictive value of developing VB of 90% and a negative predictive value of 100%. These high predictive values were also maintained in the subgroup of patients negative for HBV-DNA at month six. The results of this study with a small sample size suggest a role of on-treatment HBsAg quantification in the management of lamivudine-treated patients. If validated prospectively in a larger patient cohort, HBsAg measurements would be a useful adjunct to optimize antiviral therapy.
2011
18
10
e468
e474
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients / Gramenzi, Annagiulia; Loggi, Elisabetta; Micco, Lorenzo; Cursaro, C; Fiorino, S; Galli, S; Gitto, Stefano; Galli, C; Furlini, G; Bernardi, Mauro; Andreone, Pietro. - In: JOURNAL OF VIRAL HEPATITIS. - ISSN 1352-0504. - 18:10(2011), pp. e468-e474. [10.1111/j.1365-2893.2011.01473.x]
Gramenzi, Annagiulia; Loggi, Elisabetta; Micco, Lorenzo; Cursaro, C; Fiorino, S; Galli, S; Gitto, Stefano; Galli, C; Furlini, G; Bernardi, Mauro; Andreone, Pietro
File in questo prodotto:
File Dimensione Formato  
HBsAg - JVH.pdf

Accesso riservato

Dimensione 152.35 kB
Formato Adobe PDF
152.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
HBsAg - JVH.pdf

Accesso riservato

Dimensione 152.35 kB
Formato Adobe PDF
152.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1237352
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact